1. Advances in the treatment of non-small cell lung cancer (NSCLC) have increased understanding of the disease biology and mechanisms of tumour progression, and improved early detection and multimodal care.
2. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients.
3. However, overall cure and survival rates for NSCLC remain low, so continued research into new drugs and combination therapies is needed to expand clinical benefit to a broader patient population.
The article is generally reliable and trustworthy as it provides an overview of the current state of knowledge on non-small cell lung cancer (NSCLC). It is written by experts in the field, citing relevant sources such as Nature Communications, New England Journal of Medicine, Cancer Cell, and Proceedings of the National Academy of Sciences USA. The article does not appear to be biased or one-sided; rather it presents both sides equally by discussing advances in treatment while also noting that overall cure and survival rates for NSCLC remain low. Furthermore, it does not contain any promotional content or partiality towards any particular treatments or therapies. The article also mentions potential risks associated with certain treatments but does not go into detail about them. Additionally, there are no unsupported claims or missing points of consideration; all claims are supported by evidence from relevant sources. Finally, there are no unexplored counterarguments or missing evidence for the claims made in the article. In conclusion, this article is reliable and trustworthy due to its comprehensive coverage of the topic and lack of bias or promotional content.